BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 31954535)

  • 1. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
    Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
    Matsuo K; Machida H; Mandelbaum RS; Grubbs BH; Roman LD; Sood AK; Gershenson DM
    Gynecol Oncol; 2019 May; 153(2):230-237. PubMed ID: 30797590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
    Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
    Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
    Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
    Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiologic features of borderline ovarian tumors in California: a population-based study.
    Morris CR; Liu L; Rodriguez AO; Cress RD; Snipes K
    Cancer Causes Control; 2013 Apr; 24(4):665-74. PubMed ID: 23314731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
    Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
    J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
    Petiot F; Descargues P; Devouassoux-Shisheboran M; You B; Rousset-Jablonski C; Raffin D; Hajri T; Gertych W; Glehen O; Philip CA; Lamblin G; Golfier F; Bolze PA
    Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():191-197. PubMed ID: 38295707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Matsuo K; Matsuzaki S; Nusbaum DJ; Maoz A; Oda K; Klar M; Roman LD; Sood AK
    Gynecol Oncol; 2021 Jan; 160(1):32-39. PubMed ID: 33196436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-grade Serous Tumors: Are We Making Progress?
    Pauly N; Ehmann S; Ricciardi E; Ataseven B; Bommert M; Heitz F; Prader S; Schneider S; du Bois A; Harter P; Baert T
    Curr Oncol Rep; 2020 Jan; 22(1):8. PubMed ID: 31989304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-grade serous ovarian carcinoma: A comprehensive literature review.
    Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
    Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.
    Gershenson DM; Bodurka DC; Lu KH; Nathan LC; Milojevic L; Wong KK; Malpica A; Sun CC
    J Clin Oncol; 2015 Aug; 33(24):2675-82. PubMed ID: 26195696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001).
    Vatansever D; Taskiran C; Mutlu Meydanli M; Gungorduk K; Akbayir O; Yalcin I; Demirkiran F; Sozen H; Ozgul N; Celik H; Onan MA; Taskin S; Oge T; Simsek T; Abboud S; Yuksel IT; Ayhan A
    J Surg Oncol; 2021 May; 123(8):1801-1810. PubMed ID: 33657253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
    Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors.
    Vancraeynest E; Moerman P; Leunen K; Amant F; Neven P; Vergote I
    Int J Gynecol Cancer; 2016 Oct; 26(8):1399-406. PubMed ID: 27465897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
    Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
    J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
    Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
    Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
    Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
    Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
    Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
    Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.